Palvella Therapeutics (PVLA) director granted 3,000 stock options at $102.19
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics director Todd C. Davis received a new stock option grant. He was awarded options to buy 3,000 shares of common stock at an exercise price of $102.19 per share, expiring on June 10, 2036. The options vest on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Davis Todd C
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 3,000 options
Exercise price: $102.19 per share
Underlying shares: 3,000 shares
+2 more
5 metrics
Options granted
3,000 options
Stock Option (Right to Buy) granted on 2026-06-10
Exercise price
$102.19 per share
Conversion/exercise price of stock option
Underlying shares
3,000 shares
Common stock underlying the option grant
Expiration date
June 10, 2036
Option expiration for this grant
Total options after grant
3,000 options
Total derivative holdings from this award following transaction
Key Terms
Stock Option (Right to Buy), grant/award acquisition, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
exercise price financial
"conversion_or_exercise_price: 102.1900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"date of the Issuer's next annual meeting of stockholders"
FAQ
What did Todd C. Davis report in his Form 4 for PVLA?
Todd C. Davis reported receiving a grant of stock options for 3,000 shares of Palvella Therapeutics common stock. These options are a compensation award and do not represent an open-market purchase or sale of existing shares.
What is the exercise price of the new PVLA stock options granted to Todd C. Davis?
The stock options granted to Todd C. Davis have an exercise price of $102.19 per share. This is the fixed price at which he may buy Palvella Therapeutics common stock if and when the options vest and are exercised.
When do Todd C. Davis’s new PVLA stock options vest?
The options vest upon the earlier of the first anniversary of the grant date or Palvella Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Todd C. Davis continuing to serve through the applicable vesting date.
Do the reported PVLA option grants involve any stock sales by Todd C. Davis?
No, the Form 4 shows only a grant of stock options classified as an acquisition. There are no reported open-market sales or purchases of Palvella Therapeutics common stock in this filing, just a compensation-related award.